Leukoreduction is the reduction of white blood cells or leukocytes from the blood or blood components being transfused to the recipient. White blood cells (also called leukocytes or immune cells) are a component of blood. ... Red blood cells (erythrocytes) are present in the blood and help carry oxygen to the rest of the cells in the body Blood is a circulating tissue composed of fluid plasma and cells (red blood cells, white blood cells, platelets). ... Blood transfusion is the taking of blood or blood-based products from one individual and inserting them into the circulatory system of another. ...
Reduces risks of fever, shaking chills, immunization to white cell, platelet and perhaps red cell antigens, reduces risk of infection with cytomegalovirus. Also reduces the risks of post-operative bacterial infections, multi-organ failure and death for some surgical operations requiring transfusions. Cytomegalovirus - Wikipedia, the free encyclopedia /**/ @import /skins-1. ...
Some studies suggest overall cost savings in transfused surgical patients.
Cons
Loss of valuable blood components.
Costs
Timeline
Universal leukoreduction is currently not available in most countries.
As of 2005, most developed nations have adopted universal leukoreduction of transfusions with the notable exception of the United States. Canada, Britain and France adopted universal leukoreduction in the late 1990s.
Reduces risks of fever, shaking chills, immunization to white cell, platelet and perhaps red cell antigens, reduces risk of infection with cytomegalovirus.
As of 2005, most developed nations have adopted universal leukoreduction of transfusions with the notable exception of the United States.
He suggested that the three consensus indications for leukoreduction, namely reduced febrile transfusion reactions, reduction of alloimmunization, and reduced exposure to cell-associated pathogens, were sufficient by themselves to justify universal leukoreduction, and that the potential of universal leukoreduction to avoid unintended patient exposure to non-leukoreduced blood provided additional justification.
Vamvakas commented that the three generally accepted indications for leukoreduction had been demonstrated in a small subset of individuals who receive transfusion, and the extrapolation of these benefits to the transfused population as a whole was without empiric support.
He spoke in favor of universal leukoreduction on the basis of the three commonly accepted indications for this procedure, and on the basis of the currently available evidence for an immunomodulatory effect of blood transfusion.
Feeds |
Contact